NIOD vs the ordinary copper peptides: what the labels don't say

Last updated 2026-07-24

what's actually different between NIOD and The Ordinary copper peptide products

NIOD and The Ordinary are sister brands under the same parent company, Deciem. That surprises people who assume they're competitors. They're not. NIOD sits at the higher price, higher concentration end of the portfolio, aimed at people who already know their skincare actives. The Ordinary is the accessible, stripped-down version of the same ingredient philosophy. NIOD's copper peptide product is called Copper Amino Isolate Serum 1% (often shortened to CAIS 2:1). The name tells you the labeled strategy: a 1% copper amino isolate concentration, formulated as a two-part or ratio system depending on the version you buy. The Ordinary's version is simpler, marketed plainly as a copper peptide serum at a lower price point, with less formulation complexity described on the label. Here's the thing neither brand gives you: neither publishes a clinical trial on the finished bottle. What you get is an ingredient concentration claim and a formulation story. The underlying molecule both products lean on, GHK-Cu, does have a real and fairly deep research record. But that record is not the same thing as a study on NIOD's serum or The Ordinary's serum. That distinction matters more than the marketing copy on either label. If you want the primary literature on GHK-Cu itself, independent of any single retail brand, that's a different reading project than comparing two Deciem products. We cover the base molecule in more depth on our ghk-cu page.

is niod copper peptide serum stronger than the ordinary's version

"Stronger" depends on what you're measuring, and cosmetic labeling doesn't make that easy. NIOD lists a 1% copper amino isolate concentration on CAIS. The Ordinary doesn't always disclose an exact percentage the same way, and formulation details (buffer system, pH, whether it's a true GHK-Cu complex or a broader copper amino acid blend) affect how much of the labeled ingredient is actually bioavailable to skin. A higher percentage on a label is not automatically a higher dose of active, functional GHK-Cu reaching the dermis. Delivery format changes absorption. Research on liposome-encapsulated GHK-Cu shows that encapsulation method measurably affects how much peptide penetrates skin layers, and that measuring that penetration accurately is still a technical challenge for researchers, more than marketers ^[1][2]. A study using capillary electrophoresis coupled with ICP-MS was developed specifically because monitoring how much GHK-Cu actually ends up inside a liposome carrier, versus free in solution, is not trivial to verify ^[3]. So when a label says 1%, that number describes what went into the formula, not what your skin absorbs. Neither Deciem brand publishes penetration data specific to their product. That's normal for cosmetics regulated as cosmetics rather than drugs, but it means the percentage war between NIOD and The Ordinary is mostly a marketing frame, not a clinical one.

does the research on ghk-cu actually apply to these serums

Partially, and with real caveats. GHK-Cu has one of the deeper peptide literatures in dermatology, which is unusual. A 2018 review in the International Journal of Molecular Sciences lays out gene expression data behind GHK-Cu's proposed regenerative and protective actions in skin tissue ^[4]. A 2020 review in Aging Pathobiology and Therapeutics specifically evaluates GHK's potential as an anti-aging peptide ^[5]. A 2025 review in BioImpacts walks through GHK as a topical anti-wrinkle peptide, and is candid about both the advantages and the open problems in getting it to work reliably in a real formulation ^[6]. That's a genuinely unusual depth of literature for a cosmetic peptide. Most serum ingredients don't have this much mechanistic backing. But almost all of it is topical-application research, ex vivo skin models, cell culture, or animal wound models, not randomized trials on a specific commercial serum bottle. A 2023 study found that GHK-Cu combined with hyaluronic acid upregulated collagen IV in fibroblast cultures and ex vivo skin tests ^[7], which is encouraging mechanistic evidence but is not the same as a finished-product clinical trial with a placebo arm and a defined NIOD or Ordinary formula. So the honest answer: the underlying peptide has real support. The specific serum you're comparing does not have its own trial. That gap is worth sitting with before you decide a higher price or percentage number settles anything.

how should i read the ingredient percentage on a copper peptide label

Read it as one input, not the whole story. A copper peptide serum's real performance depends on concentration, the specific complex used, pH and stabilization, and how the formula is packaged (some copper complexes are light- and air-sensitive). Oxidation matters here in a way that's easy to miss. Copper compounds can degrade or interact with other actives (notably vitamin C and strong acids) if formulated or stored poorly. Neither NIOD nor The Ordinary publishes third-party stability testing data publicly, so you're relying on brand assurances about shelf stability, not published assay data. A genuinely useful habit: check the ingredient list order (INCI lists ingredients by descending concentration above 1%, so where copper peptide sits on the list gives a rough clue), check the batch/expiration date, and avoid layering copper peptides directly with high-dose vitamin C or strong acids in the same routine, since that combination is a known formulation conflict, not a proven skin-safety hazard, but one worth avoiding for stability reasons alone.

topical serums vs injectable ghk-cu, why this comparison only covers one lane

This is the single most important thing to separate out. NIOD and The Ordinary are both topical, over-the-counter cosmetic products. Injectable or subcutaneous GHK-Cu, sometimes discussed in longevity and recovery contexts, is a completely different product category with different oversight, different absorption mechanics, and a different (and thinner) safety record. Much of the deep dermatology literature on GHK-Cu, including the wound-healing and anti-aging studies cited throughout this article, was generated using topical application, cell culture, or animal injection models, not human injectable use ^[4][6][8]. A 2017 study on GHK-Cu liposomes accelerating scald wound healing in mice, for example, used topical liposomal application and measured cell proliferation and angiogenesis in the wound bed ^[8]. That's a topical route, in an animal model, for an acute burn wound. It says nothing about whether a subcutaneous injection in a healthy adult for anti-aging purposes carries the same benefit or risk profile. Injectable peptide use in orthopedic and sports medicine contexts is a newer and much less regulated space. A 2026 primer in The American Journal of Sports Medicine describes injectable peptide therapy as an emerging area physicians are being asked to understand, explicitly because patients are self-sourcing and requesting these compounds outside of FDA-approved indications ^[9]. A companion 2026 review in Sports Medicine on musculoskeletal and athletic performance peptide use frames the safety and efficacy picture as still unsettled for most unapproved peptide products in this category ^[10]. If you're specifically researching injectable use rather than a facial serum, read our pages on ghk-cu-peptides-injections and ghk-cu-peptide-injection-before-and-after before assuming anything from a NIOD or Ordinary serum review transfers over. It doesn't.

is copper peptide serum regulated as a drug or a cosmetic

In the US, both NIOD and The Ordinary copper peptide serums are sold and regulated as cosmetics, not drugs. That means the FDA doesn't require them to prove efficacy claims through clinical trials before sale, the way it does for approved drugs. The relevant legal line is whether a product's "intended use" claims cross into drug territory, which FDA defines partly through labeling and marketing claims under 21 CFR 201.128 ^[11]. This is different from compounded or provider-dispensed GHK-Cu preparations, which fall under a separate regulatory framework entirely. Under 21 U.S.C. 353a, licensed pharmacies can compound certain drug preparations for individual patients under a prescriber's order, using substances that appear on FDA's bulk drug substance lists ^[12]. The 503A bulks list is codified at 21 CFR 216.23 and the 503B list (for outsourcing facilities that compound at larger scale) at 21 CFR 216.24 ^[13][14]. FDA also maintains a public list of bulk substances nominated for compounding consideration, which is a different and earlier-stage list than the finalized bulks lists ^[15][16]. The practical takeaway: a cosmetic serum bought online and a provider-dispensed compounded GHK-Cu preparation are not the same regulatory animal, even if both contain "GHK-Cu" somewhere on the label. Don't let the shared name blur the oversight difference.

what does the wound-healing and dermatology literature on ghk-cu actually show

This is where GHK-Cu earns its reputation as an unusually well-studied peptide, at least compared to most trendy cosmetic ingredients. The 2008 foundational paper on GHK and tissue remodeling in the Journal of Biomaterials Science laid out much of the early mechanistic case for GHK's role in wound healing and tissue repair signaling ^[17]. Since then, the animal and cell-model literature has grown substantially. A 2017 study specifically tested GHK-Cu liposomes on scald wounds in mice and reported accelerated healing tied to increased cell proliferation and angiogenesis in the wound area ^[8]. Separately, a 2025 study on an injectable hydroxyapatite microsphere filler loaded with GHK-Cu evaluated anti-inflammatory and antioxidant effects in a dermal filler context, which is a device/filler application, not a cosmetic serum ^[18]. A 2025 paper on copper-GHK-hyaluronan conjugates reported antioxidant properties along with osteogenic and angiogenic effects in combined lab models ^[19]. Outside skin specifically, GHK-Cu has been studied in a genuinely wide range of disease and injury models: colitis in a 2025 Frontiers in Pharmacology study ^[20], cigarette-smoking-induced skeletal muscle dysfunction in a 2023 Journal of Cachexia, Sarcopenia and Muscle paper ^[21], bleomycin-induced pulmonary fibrosis in a 2020 Life Sciences study ^[22], silicosis-related lung inflammation in a 2024 Redox Biology paper ^[23], and lipopolysaccharide-induced acute lung injury in a 2016 Oncotarget study ^[24]. None of these are skin-cosmetic studies, but they show the molecule has a broad research footprint across inflammation and tissue repair biology, which is part of why dermatology researchers keep returning to it. What's missing across nearly all of this: large human randomized controlled trials on finished cosmetic products, at NIOD's or The Ordinary's specific concentrations, with blinded outcome assessment. That gap isn't unique to these two brands. It's close to universal in the cosmetic peptide category.

does copper accumulation matter if i'm just using a topical serum

For a topical serum used as directed, the accumulation concern is low but not zero, and it's a different risk profile than injectable or oral copper exposure. Topical copper peptide absorption through intact skin is limited, and the deeper penetration studies (liposome encapsulation research, for instance) exist precisely because getting meaningful amounts of GHK-Cu through the skin barrier is technically hard, not effortless ^[1][2][3]. That said, copper is not a substance to treat as automatically benign at any dose or route. Systemic copper overload is a recognized clinical concern in other contexts (notably in genetic conditions like Wilson disease, and in cases of chronic high-dose supplementation), and the honest position is that nobody has published long-term accumulation data specific to years of daily topical copper peptide serum use in the general population. That absence of data isn't reassurance. It's just an unstudied area. If you're using a topical serum once or twice daily as one part of a routine, the realistic exposure is small compared to dietary copper intake. If you're combining topical use with any injectable, oral, or IV copper-containing product, or you have a known copper metabolism condition, that's a different conversation and one worth having with a clinician rather than inferring from a serum label. Our ghk-cu-side-effects page goes into more of what's actually documented, and what isn't, across both routes.

niod vs the ordinary copper peptides: side by side

which one should i actually buy

If you're choosing purely between these two Deciem products, price and formulation preference matter more than any efficacy claim, because neither has published head-to-head human trial data against the other. The Ordinary's version is the reasonable starting point if you want to try a copper peptide serum without much financial commitment. NIOD's version costs more and offers a higher labeled concentration and more formulation options, which may appeal if you already tolerate copper peptides well and want to experiment with a stronger version. What neither will give you is drug-grade oversight or a guarantee of dose consistency batch to batch, because cosmetics aren't held to that standard the way compounded pharmaceutical preparations are. If your actual interest is in GHK-Cu's researched mechanisms for wound healing, collagen signaling, or recovery rather than a specific retail serum, that's a different sourcing question, and one where a provider-reviewed, pharmacy-dispensed route matters more than which Deciem bottle you pick. Copper Peptide Direct's review process exists for people at that stage: comparing an over-the-counter cosmetic against a pharmacy-fulfilled, provider-reviewed option, not comparing two drugstore-adjacent serums against each other. For dosing frameworks used in provider-reviewed protocols (distinct from a serum's "apply twice daily" label), see our ghk-cu-dosage page. If you're ready to look at sourcing beyond retail cosmetics, our buy-ghkcu page covers what a provider-reviewed, pharmacy-fulfilled route actually looks like.

Frequently asked questions

Is NIOD owned by the same company as The Ordinary?

Yes. Both NIOD and The Ordinary are brands under the same parent company, Deciem. They're often positioned as different tiers within the same ingredient philosophy: NIOD skews toward higher concentrations, more complex formulation systems, and higher prices, while The Ordinary is the accessible, simplified entry point.

What percentage of copper peptide is in NIOD's serum?

NIOD's Copper Amino Isolate Serum is labeled at 1% copper amino isolate concentration. That percentage describes formula content, not confirmed skin absorption. Penetration research on GHK-Cu shows delivery method (like liposome encapsulation) significantly affects how much reaches skin layers, separate from the labeled percentage ^[2][3].

Does The Ordinary's copper peptide serum work as well as NIOD's?

There's no published head-to-head clinical trial comparing the two finished products, so nobody can say definitively. Both rely on the same underlying GHK-Cu research base. The practical differences are price, labeled concentration, and formulation complexity, not proven efficacy differences from controlled human trials.

Can I use copper peptide serum with vitamin C or retinol?

Copper compounds can be chemically unstable when combined with strong vitamin C formulations or certain acids, mainly a formulation stability concern rather than a proven skin-safety hazard. Most brands recommend separating copper peptide use from vitamin C by time of day (one AM, one PM) to avoid degrading either ingredient.

Is topical copper peptide serum the same as injectable GHK-Cu?

No. Topical serums are cosmetics with limited skin penetration, while injectable GHK-Cu is a different route entirely, discussed in orthopedic and sports medicine literature as an emerging, largely unregulated practice ^[9][10]. Evidence from one route does not transfer to the other; treat them as separate products with separate risk profiles.

How is copper peptide serum regulated in the US?

As a cosmetic, not a drug, under FDA's framework distinguishing intended use claims (21 CFR 201.128) ^[11]. Cosmetics don't require pre-market efficacy trials the way drugs do. Compounded, provider-dispensed GHK-Cu preparations fall under a separate framework via 21 U.S.C. 353a and the FDA bulk drug substance lists ^[12][13][14].

Does GHK-Cu actually help with wrinkles or skin aging?

There's real mechanistic and animal/cell-model support: reviews describe GHK-Cu's proposed anti-aging and anti-wrinkle actions through gene expression and collagen pathways ^[1][5][6]. But most of this evidence is topical-application lab and animal research, not large-scale human trials on a specific commercial serum, so claims should be read as promising, not settled.

Is copper peptide serum safe to use every day long-term?

Short-term topical use appears low-risk based on the absorption and formulation literature, but there's no published long-term (multi-year) human accumulation data specific to daily topical copper peptide serum use. That's an absence of data, not proof of safety, so moderate, as-directed use is the more conservative approach.

What's the difference between cosmetic-grade and provider-dispensed GHK-Cu?

Cosmetic-grade serums (like NIOD or The Ordinary) are unregulated for efficacy claims and sold over the counter. Provider-dispensed preparations come through licensed pharmacy compounding under 21 U.S.C. 353a, using substances from FDA's bulk drug lists (21 CFR 216.23, 216.24), with prescriber oversight ^[12][13][14]. These are legally and practically different products.

Why does GHK-Cu have so much more research than other cosmetic peptides?

GHK-Cu has been studied across an unusually wide range of biology beyond skin, including lung fibrosis, colitis, skeletal muscle dysfunction, and acute lung injury models ^{[20][21][22][23][24]}, alongside its dermatology and wound-healing literature ^[1][8][17]. That breadth reflects its role as a naturally occurring copper-binding peptide, not a marketing invention.

Should I worry about copper toxicity from a copper peptide serum?

For typical topical use, systemic copper exposure is likely minimal since skin penetration is limited ^[2][3]. Copper is not automatically benign at any dose or route, though; people with known copper metabolism disorders, or those combining topical use with oral, IV, or injectable copper products, should discuss this with a clinician rather than assume serum-level exposure is negligible.

Which costs more, NIOD or The Ordinary copper peptide serum?

NIOD's Copper Amino Isolate Serum sits at a higher price tier than The Ordinary's copper peptide product, consistent with NIOD's general positioning as Deciem's more concentrated, more expensive line. Neither publishes a cost-per-clinical-outcome figure, since neither has published trial data on the finished product.

Sources

1. International Journal of Molecular Sciences, 2018 (PMID 29986520): Reviews gene expression data behind GHK-Cu's proposed regenerative and protective actions in tissue.
2. Molecules, 2025 (PMID 39795193): Discusses the technical challenge of accurately measuring skin permeation of liposome-encapsulated GHK-Cu.
3. Pharmaceutics, 2023 (PMID 37896245): Evaluates liposomes as delivery carriers for GHK-Cu tripeptide in cosmetic formulations.
4. Electrophoresis, 2024 (PMID 39451062): Developed a CE-ICP-MS/MS method to monitor GHK-Cu encapsulation levels inside liposomes.
5. Aging Pathobiology and Therapeutics, 2020 (PMID 35083444): Reviews GHK's potential as an anti-aging peptide.
6. BioImpacts, 2025 (PMID 39963574): Reviews topically applied GHK as an anti-wrinkle peptide, including advantages and unresolved formulation problems.
7. Journal of Cosmetic Dermatology, 2023 (PMID 37062921): Found GHK-Cu combined with hyaluronic acid upregulated collagen IV in fibroblast and ex vivo skin tests.
8. Wound Repair and Regeneration, 2017 (PMID 28370978): GHK-Cu liposomes accelerated scald wound healing in mice via increased cell proliferation and angiogenesis.
9. The American Journal of Sports Medicine, 2026 (PMID 41476424): Frames injectable peptide therapy as an emerging area physicians must understand due to patient self-sourcing.
10. Sports Medicine, 2026 (PMID 41966639): Reviews safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injury and athletic performance, noting an unsettled evidence picture.
11. eCFR, 21 CFR 201.128: Defines how FDA determines a product's intended use, relevant to the cosmetic vs drug regulatory line.
12. Cornell Legal Information Institute, 21 U.S.C. 353a: Establishes the legal framework for licensed pharmacy compounding of drug preparations for individual patients.
13. eCFR, 21 CFR 216.23: Codifies the 503A bulk drug substances list used in pharmacy compounding.
14. eCFR, 21 CFR 216.24: Codifies the 503B bulk drug substances list for outsourcing facility compounding.
15. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: Describes FDA's process and criteria for bulk drug substances used in 503A compounding.
16. FDA, Bulk Drug Substances Nominated for Use in Compounding: Lists bulk substances nominated for compounding consideration, distinct from the finalized bulks lists.
17. Journal of Biomaterials Science, Polymer Edition, 2008 (PMID 18644225): Foundational paper describing GHK's proposed role in tissue remodeling and wound healing.
18. Colloids and Surfaces B: Biointerfaces, 2025 (PMID 40716276): Evaluated an injectable hydroxyapatite microsphere filler loaded with GHK-Cu for anti-inflammatory and antioxidant effects.
19. Bioconjugate Chemistry, 2025 (PMID 40123442): Reported antioxidant, osteogenic, and angiogenic synergistic effects of copper-GHK-hyaluronan conjugates.
20. Frontiers in Pharmacology, 2025 (PMID 40672369): Studied beneficial effects of GHK-Cu in an experimental model of colitis.
21. Journal of Cachexia, Sarcopenia and Muscle, 2023 (PMID 36905132): Found GHK-Cu rescued cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway.
22. Life Sciences, 2020 (PMID 31809714): Reported protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative and anti-inflammatory pathways.
23. Redox Biology, 2024 (PMID 38879894): Found the GHK-Cu tripeptide complex attenuated lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6.
24. Oncotarget, 2016 (PMID 27517151): Found the GHK-Cu complex ameliorated lipopolysaccharide-induced acute lung injury in mice.